NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free ORMP Stock Alerts $2.35 +0.02 (+0.86%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$2.34▼$2.4350-Day Range$2.20▼$3.5852-Week Range$1.67▼$5.25Volume31,031 shsAverage Volume168,113 shsMarket Capitalization$95.22 millionP/E Ratio16.79Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Oramed Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Read More ORMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORMP Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comORMP Apr 2024 2.500 putMarch 9, 2024 | finance.yahoo.comOramed Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 21, 2024 | msn.comOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopFebruary 20, 2024 | finanznachrichten.deOramed Pharmaceuticals Inc.: Oramed Letter to ShareholdersFebruary 20, 2024 | prnewswire.comOramed Letter to ShareholdersJanuary 24, 2024 | finance.yahoo.comORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery PlatformNovember 28, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.November 2, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21October 6, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agoSeptember 21, 2023 | finance.yahoo.comOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyAugust 2, 2023 | finance.yahoo.comOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyJuly 25, 2023 | jp.reuters.comOramed Pharmaceuticals, Inc.June 20, 2023 | finance.yahoo.comOramed to Present at the 83rd American Diabetes Association ConferenceJune 17, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansMay 30, 2023 | finance.yahoo.comORMP: Advancing Development Efforts in ChinaMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)May 18, 2023 | msn.comCanaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold RecommendationMay 18, 2023 | finance.yahoo.comOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitMay 16, 2023 | msn.comOramed Surges on New Diabetes TreatmentMay 15, 2023 | msn.comWhy Oramed Pharmaceuticals Shares Are Trading Higher TodayMay 15, 2023 | finance.yahoo.comOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in ChinaMay 3, 2023 | msn.comInvesting millions, Ben Shapiro joins board of Oramed PharmaceuticalsMay 2, 2023 | marketwatch.com8-K: ORAMED PHARMACEUTICALS INC.May 2, 2023 | finance.yahoo.comConservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug CompanyMay 1, 2023 | finance.yahoo.comOramed Appoints Ben Shapiro to its Board of DirectorsSee More Headlines Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.14 Trailing P/E Ratio16.79 Forward P/E RatioN/A P/E GrowthN/ANet Income$5.53 million Net MarginsN/A Pretax Margin379.70% Return on Equity-7.15% Return on Assets-5.70% Debt Debt-to-Equity RatioN/A Current Ratio3.06 Quick Ratio3.06 Sales & Book Value Annual Sales$1.34 million Price / Sales71.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.58Miscellaneous Outstanding Shares40,520,000Free Float35,657,000Market Cap$95.22 million OptionableOptionable Beta1.81 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Nadav Kidron Esq. (Age 50)President, CEO & Executive Chairman Comp: $754.3kMr. David Silberman CPA (Age 40)CFO & Treasurer Comp: $259.53kDr. Miriam Kidron Ph.D. (Age 84)Chief Scientific Officer & Director Comp: $503.95kMr. Joshua Hexter (Age 54)Chief Operating & Business Officer Comp: $326.94kKey CompetitorsSeres TherapeuticsNASDAQ:MCRBBarinthus BiotherapeuticsNASDAQ:BRNSGeneluxNASDAQ:GNLXConnect BiopharmaNASDAQ:CNTBMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInstitutional OwnershipBML Capital Management LLCBought 480,267 shares on 1/30/2024Ownership: 3.127%View All Institutional Transactions ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed in 2024? Oramed Pharmaceuticals' stock was trading at $2.31 on January 1st, 2024. Since then, ORMP shares have increased by 2.6% and is now trading at $2.37. View the best growth stocks for 2024 here. Are investors shorting Oramed Pharmaceuticals? Oramed Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average daily volume of 174,600 shares, the short-interest ratio is presently 3.3 days. View Oramed Pharmaceuticals' Short Interest. When is Oramed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ORMP earnings forecast. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN). How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ORMP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
